Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view
2015 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, Vol. 50, no 6, 727-739 p.Article, review/survey (Refereed) Published
Neuroendocrine tumors (NETs) comprise a heterogenous group of neoplasms with variable clinical expression and progression. The primary tumors most frequently occur in the lungs, intestine and the pancreas. The NET incidence is approximately 6.1/100,000 per year with a prevalence higher than 35/100,000 per year. A NET may be functioning with symptoms related to hormone overproduction or non-functioning, not presenting any hormone-related symptoms. From the early 1980s and onwards, Uppsala University Hospital has contributed significantly to diagnosis, just to mention immunohistochemistry, radio-immunoassays for hormones and peptides and molecular imaging. On the therapeutic side, treatments with cytotoxics as well as biologicals such as, somatostatin analogs and interferons have been evaluated. We have furthermore been involved in important phase III trials for registration of so called, new targeted agents such as, RADIANT-3 and RADIANT-2. Our group were also the first to localize the gene for MEN I on chromosome 11 locus q13. Most recent developments have been the establishments of new biomarkers such as, olfactory receptor E51E1 as well as micro-RNAs in carcinoid tumors of the intestine and lung. A new oncolytic virus, Ad-Vince, for treatment of most NETs has been developed and is ready for the clinic. Furthermore, we have been involved in establishing Nordic and international collaborations. Today, NETs is an area with rapid development and recognized by international organizations at conferences, with large attendance. The Nordic countries continue to be significant contributors to the field.
Place, publisher, year, edition, pages
2015. Vol. 50, no 6, 727-739 p.
cytokines, genetics, hormones-and-receptors, immunology, oncologyclinical, small intestinal disorders
Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-257301DOI: 10.3109/00365521.2015.1033001ISI: 000354217900013PubMedID: 25855088OAI: oai:DiVA.org:uu-257301DiVA: diva2:839441